PPPAIMT-Crest/help/study_questionnaire.md

6.5 KiB
Raw Blame History

Study Questionnaire — Survey Questionnaire Version 01 (Date: 14/10/2026)

CREST Pvt. Ltd. — Confidential

Study title: Physicians' Perceptions of the Impact of an Extended-Dose Pack versus Regular Pack on Adherence to Inhaled Maintenance Medication in Asthma and COPD: A Cross-Sectional Survey


Section 1: Basic Demographics / Doctor Details

  • Name: ______
  • Qualification (single choice): MBBS / MD (Chest) / DM (Pulmo / DNB / DCH) / MD (Med) / DNB (Med) / Any other (specify): ______
  • Years of Practice: ______
  • Practice setting (multi-select): Private Clinic / Private Hospital / Govt. Hospital / Other (please specify): ______
  • Specialization (single choice): Chest Physician / Consulting Physician / Other (specify): ______
  • City: ______
  • State (dropdown): all Indian states and union territories

Section 2: Physician Practice Profile

  1. On an average, how many patients do you see per month? ______
  2. Approximately how many asthma patients do you manage per month?
    • New patients: ___
    • Follow-up/old patients: ___
  3. Approximately how many COPD patients do you manage per month?
    • New patients: ___
    • Follow-up/old patients: ___

Section 3: Foracort Prescribing Pattern

  1. Approximately what proportion of your asthma patients receive Formoterol/Budesonide? ___ %

  2. Approximately what proportion of your COPD patients receive Formoterol/Budesonide? ___ %

  3. For how long have you been prescribing the Extended-Dose Pack to your patients with asthma and/or COPD? (single choice)

    • Less than 6 months
    • 6 months to less than 1 year
    • More than 1 year
  4. Among your patients receiving Formoterol/Budesonide, approximately what proportion do you prescribe (each column must total 100%):

    Regular Pack: Formoterol/Budesonide 200 & 400 mcg – Rotacaps (pack of 30) and MDI (120 doses). Extended-Dose Pack: Formoterol/Budesonide 200 & 400 mcg – Rotacaps (pack of 60) and MDI (180 doses).

Pack type Product Pack info Asthma COPD
Regular Pack Formoterol/Budesonide 200 & 400 mcg pMDI 120 doses (unit dose cost same for 120 and 180 dose packs) ___% ___%
Regular Pack Rotacap Pack of 30 (unit dose cost same for 30 and 60 dose pack) ___% ___%
Extended-Dose Pack Formoterol/Budesonide 200 & 400 mcg pMDI 180 doses (unit dose cost same for 120 and 180 dose packs) ___% ___%
Extended-Dose Pack Rotacap Pack of 60 (unit dose cost same for 30 and 60 dose pack) ___% ___%
Total 100% 100%

Section 4: Physician Assessment of Adherence

  1. Based on your clinical experience, approximately what proportion of patients are adherent to their prescribed treatment? (Estimate out of 100 patients.)

    Note: A patient is considered "adherent" if the physician believes the patient takes at least 75% of the prescribed inhaled maintenance medication doses during a typical month of treatment.

    Regular Pack: Formoterol/Budesonide 200 & 400 mcg – Rotacaps (pack of 30) and MDI (120 doses). Extended-Dose Pack: Formoterol/Budesonide 200 & 400 mcg – Rotacaps (pack of 60) and MDI (180 doses).

Pack type Product Asthma COPD
Regular Pack Formoterol/Budesonide 200 & 400 mcg pMDI (120 doses) ___ / 100 ___ / 100
Regular Pack Rotacap (pack of 30) ___ / 100 ___ / 100
Extended-Dose Pack Formoterol/Budesonide 200 & 400 mcg pMDI (180 doses) ___ / 100 ___ / 100
Extended-Dose Pack Rotacap (pack of 60) ___ / 100 ___ / 100
  1. Compared with patients receiving the regular pack, adherence among patients receiving the extended-dose pack is: (single choice)
    • Much better
    • Somewhat better
    • No difference
    • Somewhat worse
    • Much worse
    • Unable to assess

Section 5: Reasons for Non-adherence

  1. In your opinion, what are the key barriers to adherence to inhaled maintenance therapy of formoterol/budesonide in your asthma and COPD patients? (multi-select)
    • Side effects
    • Lack of understanding of the need for regular treatment
    • Delay in refill due to poor accessibility
    • Perception that medication is not required when symptoms improve
    • Fear/concerns about long-term medication
    • Cost
    • Difficulty remembering to take doses
    • Inhaler technique difficulties
    • Patient lifestyle/work-related factors
    • Other (specify): ______

Section 6: Patient Characteristics Associated with Adherence

  1. Which patients, in your opinion, are most likely to benefit from an Extended-dose pack? (multi-select)
    • Elderly patients
    • Difficulty accessing the pharmacy for a refill (e.g., remote location)
    • Patients with frequent exacerbations
    • Patients frequently forgetting doses
    • Patients taking multiple medications
    • Patients with poor disease awareness
    • All patients requiring long-term maintenance therapy
    • Busy lifestyle / working professional
    • Frequent travellers
    • Caregiver-dependent patients
    • Other: ______

Section 7: Physician Perspective on the Extended-Dose Pack

  1. What do you consider the main advantages / disadvantages of the Extended-Dose Pack compared to the Regular Pack?

    • Advantages: ______
    • Disadvantages: ______
  2. Overall, how would you rate the Extended-Dose Pack compared with the Regular Pack with respect to the following? (Likert scale per row: Strongly disagree / Disagree / Neither agree nor disagree / Agree / Strongly agree)

    1. Using an Extended-Dose Pack is more convenient for patients
    2. Using an Extended-Dose Pack reduces the frequency of medication refills
    3. Using an Extended-Dose Pack improves medication adherence
    4. Using an Extended-Dose Pack helps in maintaining treatment continuity
    5. Using an Extended-Dose Pack improves patient satisfaction
    6. Using an Extended-Dose Pack helps achieve better disease control
    7. Using an Extended-Dose Pack is more cost-beneficial for patients because it reduces the frequency of doctor visits
    8. Using an Extended-Dose Pack may be detrimental because it can delay follow-up visits with the doctor
    9. Patients are reluctant to bear the higher initial purchase amount
    10. Higher chance of damage to Rotacaps due to humidity in the extended-dose pack

    Note: In the source PDF, rows 9 and 10 appear without the rating options (the page appears cut off); they are presumably meant to use the same 5-point scale.